眼科短期承压，牙科业务/爱康健持续发力。①眼科业务收入 12.11 亿港 元（-4.34%），其中香港眼科业务总计-2.09%，屈光手术量下滑与手术组 合变动下手术单价提升相抵；内地眼科业务总计-6.93%，主要系手术单 价就市况而下调（-16.97%）；②牙科业务收入 5.07 亿港元（+18.50%） 维持强劲增长，主要系主打港人医疗的内地爱康健业务持续扩张，长者 医疗券政策自 2024 年 8 月 14 日正式落地，年内直接收入 1510 万港元、 患者额外消费 1830 万港元；③其他医疗服务收入 0.38 亿港元（-19.87%）， 主要系香港肿瘤中心战略收缩；④视力辅助产品收入 1.56 亿港元（- 3.82%）主要系内地产品需求降低。 深港融合加速，差异化跨境医疗路径已现雏形。公司重点布局深港口岸 医疗生态，2024 年为业务调整重组阶段：①深圳爱康健口腔医院纳入大 湾区长者医疗券试点，政策红利释放增量空间，持续受益于港人北上需 求；②年内关停业绩表现欠佳的佛山眼科医院、南山眼科诊所（与爱康 健沈虹门诊合并）和深圳两间亏损的牙科诊所，同时为维持覆盖面，拟 在福田口岸新建 1 间牙科诊所，2025 ...

Financial Performance - For the six months ended June 30, 2024, the core medical service revenue was HK$922.5 million, a slight decrease of 0.9% compared to HK$930.8 million in the same period last year[11]. - Profit attributable to equity holders of the Company increased by 3.4% to HK$30.8 million in 1H2024, up from HK$29.8 million in the same period last year[10]. - Excluding the profit from the sales of medical consumables segment, profit from core medical services increased by 31.7% to HK$30.8 million in 1H2024 compared to HK$23.4 million last year[10]. - Gross profit margin for 1H2024 was 31.3%, a decrease of 0.3 percentage points from 31.6% in 1H2023[8]. - Adjusted profit for the period attributable to equity holders of the Company was HK$48.6 million, representing a 54.0% increase from HK$31.6 million in the previous year[8]. - EBITDA for 1H2024 was HK$181.8 million, an increase of 11.8% compared to HK$162.6 million in 1H2023[8]. - The profit for the period was HK$48.6 million, a significant increase from HK$19.4 million in the same period last year, marking a 100% growth[8]. - Total revenue for 1H2024 was HK$922.5 million, a decrease of 2.9% from HK$950.3 million in the same period of 2023[24]. - Total revenue for the six months ended June 30, 2024, was HK$922,501,000, a decrease of 2.4% compared to HK$950,263,000 in 2023[79]. - Profit for the period for the six months ended June 30, 2024, was HK$30,763,000, compared to HK$37,997,000 for the same period in 2023, reflecting a decrease of approximately 19.3%[88]. Revenue Breakdown - Revenue from dental services in Shenzhen increased due to cross-border consumption trends among Hong Kong citizens[11]. - Revenue from the sales of COVID-19 related medical consumables dropped to zero in 1H2024 from HK$19.4 million in the same period last year due to relaxed testing requirements[15]. - Revenue from Hong Kong medical business decreased by 9.0% to HK$427.1 million in 1H2024 from HK$469.5 million in 1H2023[28]. - Revenue from Mainland China ophthalmic services and dental services increased by 7.4% to HK$495.4 million in 1H2024 from HK$461.4 million in 1H2023[29]. - Revenue from ophthalmic services in Mainland China decreased by 7.5% to HK$270.8 million in 1H2024 from HK$292.8 million in the same period last year[30]. - Revenue from dental services increased by 28.0% to HK$246.4 million in 1H2024 from HK$192.5 million in the same period last year[35]. - Revenue from sales of medical consumables was absent in 1H2024 compared to HK$19.4 million in the same period last year[35]. - Revenue generated by operations in Hong Kong accounted for 46.3% of total revenue in 1H2024, down from 51.4% in the same period last year[38]. - Revenue from Mainland China increased to 53.7% of total revenue for 1H2024, up from 48.6% in 1H2023, driven by a 33.3% growth in dental services revenue[39]. Cost and Expenses - Total cost of revenue decreased by 2.6% from HK$650.1 million in the first half of 2023 to HK$633.4 million in the first half of 2024[54]. - Gross profit for the first half of 2024 was HK$289.1 million, a decrease of 3.7% from HK$300.2 million in the same period last year, with a gross profit margin of 31.3%[57]. - Selling expenses decreased by 12.2% from HK$69.1 million in the first half of 2023 to HK$60.6 million in the first half of 2024, representing 6.6% of total revenue[58]. - Administrative expenses totaled HK$159.4 million in the first half of 2024, down 10.8% from HK$178.7 million in the same period last year[58]. - Employee costs rose to HK$266.0 million in 1H2024 from HK$244.2 million in the same period last year, despite a decrease in the number of employees from 2,221 to 2,192[66]. Cash Flow and Financial Position - Cash and cash equivalents stood at HK$465.3 million, with short-term deposits of HK$33.7 million and borrowings of HK$1.2 million as of June 30, 2024[69]. - Net cash generated from operating activities was HK$135.4 million in 1H2024, a decrease from HK$195.4 million in the same period of 2023, primarily due to increased working capital requirements[72][74]. - Net cash used in investing activities amounted to HK$73.4 million in 1H2024, down from HK$168.2 million in 1H2023, with approximately HK$84.0 million spent on property, plant, and equipment[73][74]. - Net cash used in financing activities was HK$103.7 million in 1H2024, slightly up from HK$102.3 million in 1H2023, including HK$32.7 million for share purchases and HK$71.8 million for lease payments[73][74]. - The Group maintained a net cash position as of June 30, 2024, with total borrowings of HK$1.2 million, down from HK$13.0 million in 2023, and an effective interest rate of 2.75%[72][74]. Strategic Developments - The company signed a strategic agreement for a "Hong Kong-style" private hospital near Shenzhen's Luohu port, expected to commence operations by the end of 2024[23]. - The new hospital will have a gross floor area of over 10,000 sq. m. and will include multiple medical departments[24]. - The Group operates a network of ten eye hospitals and multiple clinics in Mainland China, optimizing organizational structure and management[17]. - The Group's investment in Shenzhen C.K.J has positioned it to capitalize on the robust demand for quality dental services in the region[18]. - The Group plans to focus on expanding ophthalmic services in Hong Kong and Mainland China, while also enhancing cross-border medical services in Shenzhen[76][77]. Shareholder Information - The Group did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the previous year[143]. - The company paid dividends amounting to HK$200,000 during the period[86]. - The weighted average number of ordinary shares in issue decreased to 1,239,070,639 in 2024 from 1,258,860,726 in 2023, a decline of 1.6%[142]. - The number of treasury shares increased from 8,074,000 shares (HK$33,910,000) on June 30, 2023, to 22,822,000 shares (HK$79,318,000) on June 30, 2024, reflecting significant repurchases during the period[180]. Regulatory and Compliance - The interim condensed consolidated financial information has not been audited and is presented in Hong Kong Dollar (HK$), rounded to the nearest thousand (HK$'000)[92]. - The Group's financial risk management policies have not undergone any significant changes since December 31, 2023[99][101]. - The Group is assessing the financial impact of new and amended standards effective for the financial year beginning on or after January 1, 2025, but is not yet in a position to determine substantial changes[98].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 C-MER Medical Holdings Limited 希瑪醫療控股有限公司 （股份代號：3309） （於開曼群島註冊成立之有限公司） 截 至2024年6月30日止六個月的中期業績 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------|-------|-------|-------|--------------------------------------|-------|-------|-----------------------------------------------|--------------| | | | | | | | | | | | | | | | | | | | | | | ...

好的,欢迎各位投资人参加华研一二联合会中举办的夏季宣传策略会。我是这个本次会的主持人,华研一二团队的编辑是陈嘉蔚。今天这一场的话,我们是很高兴请到了喜马研科的领导来跟我们去做这次交流。与我一同在线的还有我们首席讲座老师。那首先还是想把时间交还给喜马的领导秦孙总,来帮我们再简单的去回顾一下公司的一些业绩,包括后续对战的一些战略。孙总。 好的,各位投资人大家好,我是西马的森井。首先感谢陆远中以及华人这边邀请组织本次这场活动。我接下来就简单的跟大家分享一下我们西马目前的一些最新的情况以及战略方向。 首先对于我们公司来说的话,因为大家对于已经上市的这些公司可能都A股的比较了解,但是我们是在香港是由国际的眼科专家林春潮教授2012年创立,然后2018年在香港主板成功上市的一家企业。 简单来说的话我们目前是香港和大湾区领先的港资的严苛连锁我们在香港的民营市场的占有率是超过20%了然后我们也是深圳最大的严苛集团之一从我们的业务布局范围来讲的话我们主要是立足湾区然后区在北京跟上海及昆明还有单独的一个医院 除了我们的眼科之外的话我们在2022年的时候开辟了我们集团的第二大主营业务也就是我们的口岸口腔业务那么从它在去年过去到20 ...

好的,欢迎各位投资人参加华研一二联合会录影中举办的夏季现场策略会。我是这个本次会的主持人,华研一二团队的编辑是陈嘉蔚。今天这一场的话,我们是很高兴请到了喜马研科的领导来跟我们去做这次交流。与我一同在线的还有我们首席讲座老师。那首先还是想把时间交还给喜马的领导秦孙总,来帮我们再简单的去回顾一下公司的一些业绩,包括后续对战的一些战略。孙总。 好的,各位投资人大家好,我是西马的分警,首先感谢陆远中以及华人这边邀请组织本次这场活动。我接下来就简单的跟大家分享一下我们西马目前的一些最新的情况以及战略方向。 首先对于我们公司来说的话,因为大家对于已经上市的这些公司可能都A股的比较了解,但是我们是在香港是由国际的眼科专家林顺潮教授2012年创立,然后2018年在香港主板成功上市的一家企业。 简单来说的话我们目前是香港和大湾区领先的港资的眼科连锁我们在香港的民营市场的占有率是超过20%然后我们也是深圳最大的眼科集团之一从我们的业务布局范围来讲的话我们主要是立足湾区然后区在北京跟上海以及昆明还有单独的一个医院 除了我们的眼科之外的话我们在2022年的时候开辟了我们集团的第二大主营业务也就是我们的口岸口腔业务那么从它在去年过去到 ...

Financial Performance - Revenue for the year ended December 31, 2023, reached HK$1,923,964,000, an increase of 11.1% compared to HK$1,731,903,000 in 2022[6]. - Core medical service revenue increased by 32.9% year-on-year to HK$1,904,531,000, marking a record high since the company's listing[13]. - Gross profit rose to HK$618,962,000, reflecting a 38.3% increase from HK$447,697,000 in the previous year[7]. - Profit before income tax was HK$124,269,000, a significant recovery from a loss of HK$11,227,000 in 2022[7]. - Net profit for the year was HK$86,335,000, compared to a loss of HK$46,225,000 in the prior year[7]. - Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 52.4% to HK$343,491,000 from HK$225,351,000[8]. - The gross profit margin improved to 32.2%, up 6.3 percentage points from 25.9% in 2022[9]. - Total revenue for the Group rose by 11.1% to HK$1,924.0 million in 2023, compared to HK$1,731.9 million in 2022, despite a significant drop in COVID-19 related medical consumables revenue[33]. Business Segments - The Group's ophthalmic business achieved a record revenue of HK$1.43 billion, representing a year-on-year growth of 15.7%[13]. - Core medical business revenue reached HK$1.9 billion, a year-on-year increase of 32.9%[14]. - Ophthalmic business revenue amounted to HK$1.43 billion, representing a year-on-year growth of 15.7%[15]. - Dental business revenue surged to HK$428.1 million, reflecting a year-on-year increase of 161.3%[18]. - Shenzhen CKJ's dental revenue rose to HK$380 million, marking a year-on-year growth of 208%[18]. - Revenue from the Mainland China ophthalmic and dental services increased by 54.9% to HK$972.4 million in 2023, compared to HK$627.9 million in 2022, with a 62.8% increase in RMB terms[49]. Market Expansion and Strategy - The Group plans to establish the Aikangjian Fukang Hospital in Luohu Port, covering an area of over 10,000 sq.m., focusing on ophthalmic and dental services, with operations commencing in phases from the second half of 2024[25][26]. - The Group aims to integrate Hong Kong's medical services with Mainland China, enhancing the quality of cross-border medical services and supporting Hong Kong residents seeking medical care in the Mainland[27]. - The Group aims to establish or acquire eye hospitals and dental clinics in Hong Kong, Shenzhen, and selected cities in Mainland China, leveraging favorable policies in the medical industry[112]. - The Group is actively seeking strategic partners for the development and distribution of myopia control products[115]. Operational Highlights - Shenzhen CKJ registered over 240,000 patient visits in 2023, with approximately 50% from Hong Kong[18]. - The average revenue per dental chair at Shenzhen CKJ reached HK$1.75 million in 2023[18]. - The Group operates a comprehensive ophthalmic services network in Hong Kong, including five day surgery centres and eight satellite clinics, under the brand "C-MER Dennis Lam"[34]. - The Group's operational adjustments and focus on core business segments have ensured a robust balance sheet amid challenging macroeconomic conditions[35]. Financial Management - The Group's strategy includes prudent management of working capital to maintain a healthy balance sheet while focusing on core business segments[33]. - The income tax expense for 2023 was HK$37.9 million, an increase of 8.3% from HK$35.0 million in 2022, primarily due to higher tax expenses from operations in Mainland China[93]. - The Group's credit risk is limited as cash and cash equivalents are held with high-credit-quality financial institutions[105]. - The current ratio improved to 1.85 times as of December 31, 2023, compared to 1.63 times in 2022, indicating better short-term financial health[117]. Shareholder Returns and Capital Management - The Board does not recommend the payment of a final dividend for the year ended December 31, 2023[178][181]. - The Group has adopted a dividend policy aimed at maintaining sufficient operating capital while providing stable and sustainable returns to shareholders[179]. - The company repurchased a total of 10,998,000 ordinary shares at an aggregate consideration of HK$41,631,058 during the year[194]. - The share repurchases were intended to enhance the net asset value per share and/or earnings per share of the company[195]. Management and Governance - Dr. Lin Shun Chao, the founder and CEO, has led the company for over ten years since its establishment[146]. - The company has expanded its management team with experienced professionals in ophthalmology and healthcare management[152]. - The Group's Chief Financial Officer, Mr. Chan Wa Ping, has over 10 years of financial and accounting experience and oversees finance, compliance, mergers and acquisitions, and investor relations[172]. - The management team has a strong academic background, with members holding advanced degrees in medicine and business administration[149][152]. Risks and Compliance - Key risks include reputation risk, customer risk, regulatory risk, price risk, and talent risk, which could materially affect the Group's operations and financial condition[184][185]. - The company complied with all relevant laws and regulations in Hong Kong, Mainland China, and the Cayman Islands in all material aspects during 2023[192]. - The company has established systems for environmental protection, ensuring compliance with environmental laws and regulations[192].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 附 註： 1 該 項 目 並 非 香 港 財 務 報 告 準 則（「香港財務報告準則」）下 計 量 表 現 的 指 標，惟 獲 管 理 層 從 營 運 角 度 廣 泛 應 用 於 監 控 公 司 業 務 表 現。其 未 必 可 與 其 他 公 司 呈 列 的 類 似 計 量 指 標 作 比 較。 C-MER EYE CARE HOLDINGS LIMITED 希瑪眼科醫療控股有限公司 （股份代號：3309） （於開曼群島註冊成立之有限公司） 截 至2023年12月31日止年度 的全年業績 | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|---------|-----------|-------- ...

| --- | --- | |------------|-----------------------------------------------------------------------------------------------------------------------------------------------------| | | | | C-MER 给瑪 | C-MER EYE CARE HOLDINGS LIMITED 希瑪眼科醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) | Stock Code 股份代號：3309 INTERIM REPORT 2023 Contents 目錄 Corporate Information 2 公司資料 Financial Highlights 5 財務概要 Management Discussion and Analysis 6 管理層討論及分析 Condensed Consolidated Interim Sta ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 C-MER EYE CARE HOLDINGS LIMITED 希瑪眼科醫療控股有限公司 （股份代號：3309） （於開曼群島註冊成立之有限公司） 截 至2023年6月30日止六個月的中期業績 | --- | --- | --- | --- | --- | |--------------------------------------------|-------|-----------------|-----------------|------------| | | | | | | | 財務概要 | | | | | | | | 截 至 6 月 30 | 日止六個月 | | | | 附 註 | 2023 年 | 2022 年 | 變 動 | | | | 千港元 | 千港元 | (%) | | | | （未 經 審 核） | （未 經 審 核） | ...

Financial Performance - The Group's revenue for the year ended December 31, 2022, reached HK$1,731,903,000, representing a 55.7% increase compared to HK$1,112,577,000 in 2021[6]. - Gross profit for the same period was HK$447,697,000, up 25.0% from HK$358,228,000 in 2021[6]. - The Group reported a loss of HK$11,227,000 for the year, an improvement from a loss of HK$46,225,000 in the previous year[6]. - Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 22.5% to HK$225,351,000 from HK$183,976,000 in 2021[6]. - The gross profit margin for the year was 25.9%, a decrease from 32.2% in 2021, reflecting a 6.3 percentage point drop[6]. - Revenue from the core medical business reached HK$1,433.6 million, up 28.9% year-on-year, driven by increasing demand for high-quality medical services[19]. - Revenue from ophthalmic services increased to HK$1,074.3 million in 2022, up 16.8% from HK$920.0 million in 2021, driven by a higher number of surgeries and increased average surgery fees in Hong Kong[41]. - Revenue from dental and other medical services surged to HK$198.3 million in 2022, a remarkable increase of 279.9% from HK$52.2 million in 2021, primarily due to the integration of the newly acquired Shenzhen CKJ business[41]. - Revenue from operations in Mainland China increased by 10.4% year-on-year to HK$627.9 million, with ophthalmic business revenue at HK$502.9 million and new dental services contributing HK$125.0 million[19]. - Revenue from medical services in Hong Kong increased by 48.1% to HK$805.7 million, up from HK$543.9 million in 2021[31]. Business Expansion and Acquisitions - The Group expanded its ophthalmic services in the Greater Bay Area (GBA) by adding three new eye centers and five optometry centers during 2022[9]. - The acquisition of Shenzhen C-MER Aikangjian Dental Group Co., Ltd. positioned the Group as one of the largest private medical groups in Shenzhen[8]. - The acquisition of Shenzhen CKJ, a major dental service group, was completed in 2022, establishing the Group as one of the largest private medical groups in Shenzhen[16]. - The Group's ophthalmic hospitals in operation increased to nine, covering five key cities in the GBA, with the opening of two new hospitals in 2022[10]. - The Group expanded its ophthalmic service network in Mainland China, establishing nine eye hospitals and two eye centres, with the ninth and tenth hospitals commencing operations in Guangzhou and Jieyang in April and August 2022, respectively[27]. - The Group plans to establish or acquire eye hospitals and dental clinics in Hong Kong, Shenzhen, and selected Mainland China cities to expand its service offerings[71]. - The Group completed the acquisition of Shenzhen CKJ, becoming the largest ophthalmic service provider in Hong Kong and one of the largest private medical service groups in Shenzhen[71]. Market Outlook and Recovery - The Group anticipates strong recovery in the consumer medical market following the resumption of cross-border travel between Mainland China and Hong Kong in early 2023[8]. - The ophthalmic business in Hong Kong experienced a rapid rebound in the second half of 2022, strengthening its leading position in the local market[9]. - The Group's dental business in Shenzhen has recovered to pre-pandemic levels, showing stable and positive growth momentum[17]. - The Group is well positioned to capture opportunities in the fast-growing consumer healthcare market in Shenzhen post-pandemic[17]. - The Group experienced a significant rebound in business in 2023 following the relaxation of COVID-19 measures, driven by strong economic and consumption activities in Mainland China[71]. Operational Highlights - Approximately 91% of the revenue from medical services in Shenzhen and other parts of Mainland China is derived from privately-paid medical services[17]. - The proportion of revenue from consumer eye services reached 72% of the Group's Mainland China ophthalmic business[17]. - The Group's core medical business achieved record high revenue, marking a significant milestone in its 10-year development[11]. - The Group's efforts in developing the GBA have been fruitful, marking a significant milestone in its 10th anniversary[8]. - The preliminary preparation for Foshan Eye Hospital is largely completed, expected to commence service within the year, increasing the number of hospitals in the GBA to six[10]. Financial Position and Capital Management - As of December 31, 2022, the Group reported cash and cash equivalents of HK$644.7 million, short-term bank deposits of HK$31.3 million, and bank borrowings of HK$34.3 million[72]. - The effective interest rate of borrowings increased to 5.49% per annum in 2022 from 2.44% in 2021, with total borrowings decreasing from HK$179.4 million in 2021 to HK$34.3 million in 2022[73]. - The current ratio as of December 31, 2022, was 1.63 times, down from 1.83 times in 2021, indicating a slight decrease in liquidity[74]. - Net cash generated from operating activities increased to HK$164.9 million in 2022, up from HK$144.4 million in 2021, attributed to an increase in business scale[74]. - The Group's diversified portfolio of businesses remained resilient despite challenges faced during the pandemic[23]. Governance and Management - The Company has a strong management team with members holding various prestigious qualifications and awards in the field of ophthalmology[106][107]. - The Company has maintained a stable executive team with no changes in directorship in the past three years[110][114]. - The Group emphasizes the importance of employee relationships and has implemented competitive compensation packages and training programs to retain key staff[135]. - The Group's remuneration policy is based on merit, qualifications, and performance, with discretionary bonuses linked to profitability[183]. Risks and Challenges - The Group's operations are significantly influenced by reputation risk, which can adversely affect market recognition and trust in services[134]. - Customer risk is a concern as the Group provides mid- to high-end medical services, making it sensitive to changes in patient preferences and economic conditions[134]. - Regulatory risk may impact the Group's operations in Hong Kong and Mainland China due to changes in government policies and regulations[134]. - Talent risk is critical, as the ability to attract and retain qualified medical professionals directly affects hospital and clinic operations[135]. Shareholder and Dividend Policy - The Board does not recommend the payment of a final dividend for the year ended December 31, 2022[132]. - The Company has adopted a dividend policy aimed at maintaining sufficient operating capital and providing stable returns to shareholders[133]. - Factors considered for dividend recommendations include the Group's financial results, liquidity position, and future operations[133]. Related Party Transactions - The Company has complied with the disclosure requirements under Chapter 14A of the Listing Rules regarding connected transactions[195]. - The independent non-executive Directors confirmed that the continuing connected transactions did not exceed their respective annual caps for the year ended 31 December 2022[194]. Strategic Initiatives - The Group aims to solidify its leadership position in the ophthalmology sector in Hong Kong through market share expansion and medical team growth[198]. - The Group's financial position was strengthened through the 2022 Placing and First Subscription, raising capital for working capital and expansion[88].